The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells

Leval, Laurence de; Rickman, David S.; Thielen, Caroline; Reyniès, Aurélien de; Huang, Yen‐Lin; Delsol, Georges; Lamant, Laurence; Leroy, Karen; Brière, Josette; Molina, Thierry Jo; Berger, Françoise; Gisselbrecht, Christian; Xerri, Luc; Gaulard, Philippe

doi:10.1182/blood-2006-10-055145

Cited by 534 publications

(499 citation statements)

References 49 publications

Supporting

Mentioning

458

Contrasting

Unclassified

Order By: Relevance

“…PTCL-NOS seems to have multiple subtypes, and approximately 20% have a genetic signature that suggests that they are closely related to angioimmunoblastic T-cell lymphoma. Angioimmunoblastic PTCL seems to arise in follicular helper T-cells, which might explain some of its histological and clinical characteristics [16].…”

Section: Diagnosis Of Peripheral T-cell Lymphomamentioning

confidence: 99%

The aggressive peripheral T‐cell lymphomas: 2015

Armitage

2015

American J Hematol

View full text Add to dashboard Cite

Background: T‐cell lymphomas make up approximately 10%–15% of lymphoid malignancies. The frequency of these lymphomas varies geographically, with the highest incidence in parts of Asia.Diagnosis: The diagnosis of aggressive peripheral T‐cell lymphoma (PTCL) is usually made using the World Health Organization classification. The ability of hematopathologists to reproducibly diagnosis aggressive PTCL is lower than that for aggressive B‐cell lymphomas, with a range of 72%–97% for the aggressive PTCLs.Risk Stratification: Patients with aggressive PTCL are staged using the Ann Arbor Classification. Although somewhat controversial, positron emission tomography scans seem to be useful as they are in aggressive B‐cell lymphomas. The most commonly used prognostic index is the International Prognostic Index. The specific subtype of aggressive PTCL is an important risk factor, with the best survival seen in anaplastic large‐cell lymphoma—particularly young patients with the anaplastic lymphoma kinase positive subtype.Risk‐Adapted Therapy: Anaplastic large‐cell lymphoma is the only subgroup to have a good response to a CHOP‐like regimen. Angioimmunoblastic T‐cell lymphoma has a prolonged disease‐free survival in only ∼20% of patients, but younger patients who have an autotransplant in remission seem to do better. PTCL‐not otherwise specified is not one disease. Anthracycline‐containing regimens have disappointing results, and a new approach is needed. Natural killer/T‐cell lymphoma localized to the nose and nasal sinuses seems to be best treated with radiotherapy‐containing regimens. Enteropathy‐associated PTCL and hepatosplenic PTCL are rare disorders with a generally poor response to therapy, although selected patients with enteropathy‐associated PTCL seem to benefit from intensive therapy. Am. J. Hematol. 90:666–673, 2015. © 2015 Wiley Periodicals, Inc.

show abstract

Section: Diagnosis Of Peripheral T-cell Lymphomamentioning

confidence: 99%

The aggressive peripheral T‐cell lymphomas: 2015

Armitage

2015

American J Hematol

View full text Add to dashboard Cite

show abstract

“…15,[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35] These include angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma with a follicular growth pattern, primary cutaneous CD4( þ ) small/ medium-sized pleomorphic T-cell lymphoma and, occasionally, peripheral T-cell lymphoma, not otherwise specified and anaplastic large cell lymphoma. 15,[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35] Clinically, primary cutaneous CD4( þ ) small/ medium-sized pleomorphic T-cell lymphoma and angioimmunoblastic T-cell lymphoma present or may present with primary cutaneous involvement. 20,[36][37][38][39][40] Other CD4( þ ) T-cell lymphomas with primary cutaneous manifestations include mycosis fungoides and its variants including Sezary syndrome, adult T-cell leukemia/lymphoma and primary cutaneous CD30 þ lymphoproliferative disorders.…”

mentioning

confidence: 99%

Follicular center helper T-cell (TFH) marker positive mycosis fungoides/Sezary syndrome

et al. 2013

View full text Add to dashboard Cite

“…55 AITL had a strong signature related to normal follicular T-helper cells and overexpression of genes related to the varied components of the microenvironment including B cells, follicular dendritic cells, extracellular matrix, and angiogenesis. 56,57 ALK-positive and -negative ALCL differ in their GEP and both are different from that of PTCL, NOS, supporting their distinction in the WHO classification. 58 NK-cell lymphomas and hepatosplenic lymphomas also have a distinctive GEP.…”

Section: Characterization Of Known Entities and Recognition Of New Camentioning

confidence: 86%

Whole genome profiling and other high throughput technologies in lymphoid neoplasms—current contributions and future hopes

Campo

2013

Modern Pathology

View full text Add to dashboard Cite

The development of high throughput technologies based on the knowledge of the human genome has opened the possibility to search for global genomic alterations in tumors responsible for their development and progression that may have important clinical implications. One of the major applications of this genomic knowledge has been the design of different types of microarray platforms for the analysis of DNA alterations and gene expression profiling (GEP). The main contributions of the DNA studies in lymphoid neoplasms include the definition of relatively characteristic genomic profiles for specific disease entities, the demonstration of common chromosomal alterations across entities, the identification of genes and pathways targeted by the altered chromosomal regions, and the identification of chromosomal alterations with prognostic implications. RNA GEP studies in these tumors have enhanced the molecular characterization of known entities and facilitated the recognition of new subtypes and categories of lymphoid neoplasms, the identification of new biomarkers and prognostic models, and the detection of oncogenic pathways with potential implications for targeted therapies. The recent development of the next generation sequencing (NGS) technologies and its application in lymphoid neoplasms already have provided an initial view of the complex landscape of somatic mutations in these tumors and some findings with important functional and clinical implications. This review addresses the major contributions and limitations of the microarray technologies in the understanding of lymphoid neoplasms and discusses how this knowledge may be transferred into the clinics. The initial results of the NGS studies are also presented.

show abstract

The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells

Cited by 534 publications

References 49 publications

The aggressive peripheral T‐cell lymphomas: 2015

The aggressive peripheral T‐cell lymphomas: 2015

Follicular center helper T-cell (TFH) marker positive mycosis fungoides/Sezary syndrome

Whole genome profiling and other high throughput technologies in lymphoid neoplasms—current contributions and future hopes

Contact Info

Product

Resources

About